NovoCure LtdNVCR
Price$15.92

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $699.2M+15.5% YoYTTM through 30 Jun 2026
Net Income -$148.6MTTM through 30 Jun 2026
Free Cash Flow -$25.4MTTM through 30 Jun 2026

Margins

Current
Gross Margin77.6%
EBITDA Margin-19.7%
Operating Margin-38.7%
Net Margin-21.3%

Returns

-21.5%ROE
-9.0%ROA

Balance Sheet Health

Debt / Equity0.71x
Current Ratio2.90x
Net Debt-$197.1Mnet cash position
Cash & Equivalents$93.7M

Quality Metrics

Altman Z-Score0.99
Piotroski F-Score3 / 9
FCF Margin-3.6%
Rule of 400.2
Earnings-Beat Rate75.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $655.4M
Diluted EPS-$1.30TTM
'19'20'21'22'23'24'25
FY2025: $-1.22

Dividend

No dividend

Capital Allocation

R&D Spend$224.7M
Capex Intensity3.2%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.